Trial Profile

An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jun 2025 Status changed from planning to not yet recruiting.
13 Feb 2025 According to a PulseSight Therapeutics media release, company announced the first close of its Series A financing with existing investor Pureos BioVentures committing new funds to support the Phase I study of PST-611.
14 Jan 2025 According to a PulseSight Therapeutics media release, study PST-611-CT1 is expected to start early Q2 2025 with a readout anticipated by the end of 2025 or early 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com